Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 10:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Claudication Clear all
Completed Phase 2 Interventional Results available

Study of LLG783 in Patients With Peripheral Artery Disease (PAD) and Intermittent Claudication

NCT03194776
View directory record Official record
Conditions
Peripheral Artery Disease (PAD); Intermittent Claudication
Interventions
LLG783, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years to 85 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Jacksonville, Florida • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Jun 25, 2026, 10:05 PM EDT
Completed No phase listed Observational

Comparative Effectiveness Research Study of Peripheral Arterial Disease (PAD)

NCT01378260
View directory record Official record
Conditions
Peripheral Arterial Disease, Claudication
Interventions
Not listed
Lead sponsor
University of Washington
Other
Eligibility
21 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
12
States / cities
Bellevue, Washington • Bellingham, Washington • Everett, Washington + 6 more
Source: ClinicalTrials.gov public record
Updated May 17, 2017 · Synced Jun 25, 2026, 10:05 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers Results available

FlowMet-R Blood Flow Measurement for the Diagnosis of Peripheral Artery Disease and Critical Limb Ischemia

NCT04120610
View directory record Official record
Conditions
Peripheral Artery Disease
Interventions
FlowMet-R, ABI, TBI
Diagnostic Test
Lead sponsor
Medtronic Endovascular
Industry
Eligibility
40 Years and older
Enrollment
195 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
5
States / cities
Des Moines, Iowa • Chesterfield, Missouri • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2025 · Synced Jun 25, 2026, 10:05 PM EDT
Not listed Phase 4 Interventional

Excellence In Peripheral Artery Disease Thrombin Receptor Antagonist Intervention In Claudication Evaluation (XLPAD-TRACE Trial)

NCT02660866
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Placebo + background APT + SMT, Vorapaxar 2.08 mg/d + background APT + SMT.
Drug
Lead sponsor
North Texas Veterans Healthcare System
Federal
Eligibility
40 Years to 90 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
12
States / cities
Tucson, Arizona • San Diego, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated May 28, 2018 · Synced Jun 25, 2026, 10:05 PM EDT
Completed Phase 2 Interventional

Trial of VLTS-589 in Subjects With Intermittent Claudication

NCT00068133
View directory record Official record
Conditions
Intermittent Claudication, Peripheral Vascular Disease
Interventions
Plasmid based Gene Transfer product-VLTS-589
Genetic
Lead sponsor
Valentis
Industry
Eligibility
40 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
20
States / cities
Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jun 25, 2026, 10:05 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

ARREST PAD (Peripheral Arterial Disease)

NCT00153166
View directory record Official record
Conditions
Arterial Occlusive Disease, Intermittent Claudication, Insulin Resistance
Interventions
atorvastatin and pioglitazone, atorvastatin/placebo, pioglitazone/placebo, placebo/placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
40 Years to 85 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 29, 2014 · Synced Jun 25, 2026, 10:05 PM EDT
Completed Not applicable Interventional Results available

DURABILITY™ Iliac Study

NCT01400919
View directory record Official record
Conditions
Peripheral Arterial Disease, Claudication
Interventions
Protégé® EverFlex™ Self-Expanding Stent System, and Protégé® GPS™ Self-Expanding Stent System.
Device
Lead sponsor
Medtronic Endovascular
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 6, 2018 · Synced Jun 25, 2026, 10:05 PM EDT
Not listed Phase 4 Interventional

Effect of Evolocumab in Functional Status and LDL Oxidation of Patients With Peripheral Arterial Disease

NCT04306081
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Evolocumab 140 mg/mL Subcutaneous Injection 1 milliliter (mL) pre-filled injector Pen x 3 for a monthly dose of 420 mg for 6 months., Placebo 1milliliter (mL) Subcutaneous Injection pre-filled injector Pen x 3 monthly for 6 months.
Drug · Other
Lead sponsor
Leonardo Clavijo
Other
Eligibility
40 Years to 85 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 11, 2020 · Synced Jun 25, 2026, 10:05 PM EDT
Completed Phase 2 Interventional Results available

Patients With Intermittent Claudication Injected With ALDH Bright Cells

NCT01774097
View directory record Official record
Conditions
Peripheral Artery Disease, Intermittent Claudication
Interventions
ALD-301, Placebo (vehicle)
Biological
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
40 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
9
States / cities
Stanford, California • Gainesville, Florida • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Jun 25, 2026, 10:05 PM EDT
Completed Not applicable Interventional Results available

Investigating Superion™ In Spinal Stenosis

NCT00692276
View directory record Official record
Conditions
Lumbar Spinal Stenosis, Intermittent Claudication
Interventions
Superion™ Interspinous Spacer, X-STOP® IPD® Device
Device
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
45 Years and older
Enrollment
391 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
32
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 28 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2020 · Synced Jun 25, 2026, 10:05 PM EDT
Completed Phase 1 Interventional

Technical Development of Cardiovascular Magnetic Resonance Imaging

NCT00064896
View directory record Official record
Conditions
Peripheral Artery Disease
Interventions
MRI
Procedure
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 29, 2017 · Synced Jun 25, 2026, 10:05 PM EDT
Terminated Phase 2 Interventional Results available

Safety, Tolerability and Efficacy of ACZ885 on Leg Artery Structure in Patients With Peripheral Artery Disease

NCT01731990
View directory record Official record
Conditions
Peripheral Artery Disease
Interventions
Canakinumab (ACZ885), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
8
States / cities
Phoenix, Arizona • Jacksonville, Florida • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced Jun 25, 2026, 10:05 PM EDT
Recruiting Phase 2 Interventional

Response to Exercise and Nitric Oxide in PAD

NCT06657976
View directory record Official record
Conditions
Peripheral Artery Disease, Exercise, Intermittent Claudication, Nitric Oxide
Interventions
Supervised Treadmill Exercise, Attention Control, Nitrate-Rich Beetroot Juice + supervised exercise therapy, Placebo + supervised exercise therapy
Behavioral · Combination Product
Lead sponsor
Northwestern University
Other
Eligibility
50 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Jun 25, 2026, 10:05 PM EDT
Recruiting Not applicable Interventional

Passive Calf Stretching Therapy in Peripheral Artery Disease

NCT06041880
View directory record Official record
Conditions
Peripheral Artery Disease, Claudication, Intermittent
Interventions
Passive calf muscle stretching device
Device
Lead sponsor
Penn State University
Other
Eligibility
40 Years to 85 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Jun 25, 2026, 10:05 PM EDT
Recruiting Phase 3 Interventional

MetfOrmin BenefIts Lower Extremities With Intermittent Claudication

NCT05132439
View directory record Official record
Conditions
Intermittent Claudication
Interventions
Metformin ER, placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
35 Years to 89 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Jun 25, 2026, 10:05 PM EDT
Completed Not applicable Interventional Results available

Tack Optimized Balloon Angioplasty Study of the Tack Endovascular System® in Below the Knee Arteries

NCT02942966
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Tack Endovascular System
Device
Lead sponsor
Philips Clinical & Medical Affairs Global
Industry
Eligibility
18 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
37
States / cities
Yuma, Arizona • Fremont, California • Denver, Colorado + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2022 · Synced Jun 25, 2026, 10:05 PM EDT
Completed Phase 1 Interventional

Arterial Imaging of Inflammation and Resolution After Endovascular Surgery

NCT03590769
View directory record Official record
Conditions
Peripheral Arterial Disease, Claudication, Intermittent, Claudication, PAD, SFA - Superficial Femoral Artery Stenosis, Iliac Artery Disease, Vascular Calcification
Interventions
18F-FDG
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 29, 2020 · Synced Jun 25, 2026, 10:05 PM EDT
Completed Phase 4 Interventional Results available

Intima Versus Adventitia Drug Delivery to Elucidate Mechanisms of Restenosis: Magnetic Resonance Imaging

NCT02807779
View directory record Official record
Conditions
Peripheral Artery Disease, Vascular Disease, Critical Limb Ischemia
Interventions
Dexamethasone infusion, Drug coated balloon, Plain balloon angioplasty
Drug · Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
35 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
San Francisco, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Jun 25, 2026, 10:05 PM EDT
Not listed Phase 1Phase 2 Interventional

Safety Study of MultiGeneAngio in Patients With Peripheral Arterial Disease (PAD)

NCT00390767
View directory record Official record
Conditions
PAD, Claudication
Interventions
MultiGeneAngio
Biological
Lead sponsor
MultiGene Vascular Systems Ltd.
Industry
Eligibility
50 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2024
U.S. locations
2
States / cities
Ann Arbor, Michigan • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 4, 2015 · Synced Jun 25, 2026, 10:05 PM EDT
Not listed Phase 3 Interventional

Claudication: Exercise Versus Endoluminal Revascularization (CLEVER)

NCT00132743
View directory record Official record
Conditions
Cardiovascular Diseases, Peripheral Vascular Diseases, Atherosclerosis
Interventions
Stent, Supervised Exercise Therapy, Cilostazol
Device · Behavioral · Drug
Lead sponsor
Joselyn Cerezo, MD
Other
Eligibility
40 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
26
States / cities
Loma Linda, California • Orange, California • Palo Alto, California + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2013 · Synced Jun 25, 2026, 10:05 PM EDT
Terminated Not applicable Interventional Results available

The Vascular Biology of Dipyridamole in Peripheral Arterial Disease (PAD)

NCT00906035
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Dipyridamole 200mg and Aspirin 25mg bid:, Dipyridamole 200 mg bid, Aspirin 25 mg bid
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 79 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
3
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 4, 2017 · Synced Jun 25, 2026, 10:05 PM EDT
Completed Phase 1Phase 2 Interventional

Safety, Efficacy, and Pharmacokinetics (PK) Study of Trans Sodium Crocetinate (TSC) in Patients With Intermittent Claudication

NCT00725881
View directory record Official record
Conditions
Intermittent Claudication
Interventions
Trans sodium crocetinate (TSC), 0.9% normal saline
Drug
Lead sponsor
Diffusion Pharmaceuticals Inc
Industry
Eligibility
40 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
7
States / cities
Birmingham, Alabama • Santa Rosa, California • Stanford, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2011 · Synced Jun 25, 2026, 10:05 PM EDT
Active, not recruiting Not applicable Interventional Results available

The MOTION Study - Treatment of LSS With the MILD Procedure

NCT03610737
View directory record Official record
Conditions
Spinal Stenosis, Lumbar Region, With Neurogenic Claudication
Interventions
MILD Procedure, Conventional Medical Management (CMM)
Device · Other
Lead sponsor
Vertos Medical, Inc.
Industry
Eligibility
50 Years to 80 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
18
States / cities
Newport Beach, California • Colorado Springs, Colorado • Lakeland, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Jun 25, 2026, 10:05 PM EDT
Completed Not applicable Interventional

Best Endovascular vs. Best Surgical Therapy in Patients With Critical Limb Ischemia

NCT02060630
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
Open surgical revascularization, Endovascular revascularization
Procedure · Device
Lead sponsor
Carelon Research
Other
Eligibility
18 Years and older
Enrollment
1,843 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
144
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 102 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Jun 25, 2026, 10:05 PM EDT